M Pellizzari1, D Hui2, E Pinato1, M Lisiero3, S Serpentini4, L Gubian5, F Figoli6, M Cancian7, C De Chirico8, E Ferroni9, F Avossa1, M Saugo1. 1. Epidemiological Service of the Veneto Region, Passaggio Gaudenzio, 1, 35131, Padua, Padova, Italy. 2. Department of Palliative Care and Rehabilitation Medicine, MD Anderson Cancer Center, Houston, TX, USA. 3. Hospital Direction, Local Health Unit n° 8, Asolo, Italy. 4. Palliative Care Unit Local Health Unit n° 3, Bassano del Grappa and Veneto Oncology Institute, Padua, Italy. 5. Information Technology Service of the Veneto Region, Venezia, Italy. 6. Palliative Care Unit, Local Health Unit n° 4, Thiene, Italy. 7. GP, Local Health Unit n° 7, Conegliano, Italy. 8. Palliative Care Unit, Local Health Unit n° 7, Pieve di Soligo, Italy. 9. Epidemiological Service of the Veneto Region, Passaggio Gaudenzio, 1, 35131, Padua, Padova, Italy. eliana.ferroni@regione.veneto.it.
Abstract
PURPOSE: The Veneto Region implemented a novel integrated home-based palliative cancer care (HPCC) program embedded in primary care. We examined the impact of timing and intensity of this program on the quality of end-of-life (EOL) care. METHODS: We selected adult cancer patients died in the Veneto Region between March and December 2013, excluding those died from haematological malignancies as well as the very elderly (85+ years). We retrieved the claim-based data on hospitalization and homecare visits, and defined two observation windows: 90 to 16 days before death to examine intensity of HPCC exposure, and the last 15 days of life to examine EOL outcomes, including hospital death, any hospital stay for medical reasons and hospital stay ≥7 days for medical reasons. Multivariate analysis was conducted using a Poisson model. RESULTS: Among the 2211 adults who died of solid tumours and received 1+ homecare visits during the exposure period, 1077 (48.7%), 552 (25.0%) and 582 (26.3%) had 0.1-1.9, 2-3.9 and 4+ homecare visits/week, respectively. The median duration between an HPCC home visit and death was 92 days (IQR 42-257 days). Hospital death occurred in 856 (38.7%) patients, while 1087 (49.2%) and 556 (25.1%) had a hospital stay and a hospital stay ≥7 days during the exposure period, respectively. In the multivariate analysis, a greater intensity of integrated HPCC (4+ visits/week) was significantly associated with a lower risk of hospital death (relative risk [RR] = 0.67, 0.59-0.76), any hospital stay (RR = 0.69, 0.62-0.77) and hospital stay ≥7 days for medical reasons (RR = 0.59, 0.49-0.71). A late activation (≤30 days before death) of HPCC was also associated with increased both hospital stay (RR = 1.26, 0.11-1.42) and hospital stay ≥7 days (RR = 1.25, 1.01-1.54). CONCLUSIONS: A greater HPCC program intensity reduces the risk of hospital death and hospital stay in the end-of-life. An early activation of this program can contribute to improve these EOL outcomes.
PURPOSE: The Veneto Region implemented a novel integrated home-based palliative cancer care (HPCC) program embedded in primary care. We examined the impact of timing and intensity of this program on the quality of end-of-life (EOL) care. METHODS: We selected adult cancerpatients died in the Veneto Region between March and December 2013, excluding those died from haematological malignancies as well as the very elderly (85+ years). We retrieved the claim-based data on hospitalization and homecare visits, and defined two observation windows: 90 to 16 days before death to examine intensity of HPCC exposure, and the last 15 days of life to examine EOL outcomes, including hospital death, any hospital stay for medical reasons and hospital stay ≥7 days for medical reasons. Multivariate analysis was conducted using a Poisson model. RESULTS: Among the 2211 adults who died of solid tumours and received 1+ homecare visits during the exposure period, 1077 (48.7%), 552 (25.0%) and 582 (26.3%) had 0.1-1.9, 2-3.9 and 4+ homecare visits/week, respectively. The median duration between an HPCC home visit and death was 92 days (IQR 42-257 days). Hospital death occurred in 856 (38.7%) patients, while 1087 (49.2%) and 556 (25.1%) had a hospital stay and a hospital stay ≥7 days during the exposure period, respectively. In the multivariate analysis, a greater intensity of integrated HPCC (4+ visits/week) was significantly associated with a lower risk of hospital death (relative risk [RR] = 0.67, 0.59-0.76), any hospital stay (RR = 0.69, 0.62-0.77) and hospital stay ≥7 days for medical reasons (RR = 0.59, 0.49-0.71). A late activation (≤30 days before death) of HPCC was also associated with increased both hospital stay (RR = 1.26, 0.11-1.42) and hospital stay ≥7 days (RR = 1.25, 1.01-1.54). CONCLUSIONS: A greater HPCC program intensity reduces the risk of hospital death and hospital stay in the end-of-life. An early activation of this program can contribute to improve these EOL outcomes.
Entities:
Keywords:
End-of-life; Home visits; Hospitalization; Palliative cancer care; Place of death
Authors: Scott A Murray; Adam Firth; Nils Schneider; Bart Van den Eynden; Xavier Gomez-Batiste; Trine Brogaard; Tiago Villanueva; Jurgen Abela; Steffen Eychmuller; Geoffrey Mitchell; Julia Downing; Libby Sallnow; Erik van Rijswijk; Alan Barnard; Marie Lynch; Frederic Fogen; Sébastien Moine Journal: Palliat Med Date: 2014-11-13 Impact factor: 4.762
Authors: Alberto Alonso-Babarro; Eduardo Bruera; María Varela-Cerdeira; María Jesús Boya-Cristia; Rosario Madero; Isabel Torres-Vigil; Javier De Castro; Manuel González-Barón Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 44.544
Authors: Jennifer W Mack; Angel Cronin; Nancy L Keating; Nathan Taback; Haiden A Huskamp; Jennifer L Malin; Craig C Earle; Jane C Weeks Journal: J Clin Oncol Date: 2012-11-13 Impact factor: 44.544
Authors: Winne Ko; Luc Deliens; Guido Miccinesi; Francesco Giusti; Sarah Moreels; Gé A Donker; Bregje Onwuteaka-Philipsen; Oscar Zurriaga; Aurora López-Maside; Lieve Van den Block Journal: BMC Cancer Date: 2014-12-16 Impact factor: 4.430
Authors: Maaike L De Roo; Anneke L Francke; Lieve Van den Block; Gé A Donker; Jose E Lozano Alonso; Guido Miccinesi; Sarah Moreels; Bregje D Onwuteaka-Philipsen; Andrea Salvetti; Luc Deliens Journal: BMC Palliat Care Date: 2014-11-27 Impact factor: 3.234
Authors: Roberta I Jordan; Matthew J Allsop; Yousuf ElMokhallalati; Catriona E Jackson; Helen L Edwards; Emma J Chapman; Luc Deliens; Michael I Bennett Journal: BMC Med Date: 2020-11-26 Impact factor: 8.775
Authors: Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton Journal: J Pain Symptom Manage Date: 2019-10-19 Impact factor: 3.612